nach oben

Child's Nervous System

Erschienen in:

01.10.2016 | Special Annual Issue

Conventional chemotherapy and perspectives for molecular-based oncological treatment in pediatric hemispheric low-grade gliomas

verfasst von: María Baro Fernández, Vanesa Pérez Alonso

Erschienen in: Child's Nervous System | Ausgabe 10/2016

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Pediatric low-grade gliomas (PLGG) are the most common primary central nervous system tumor in children. Patients in whom gross total resection can be achieved have an excellent overall (OS) and event-free survival (EFS) and do not require adjuvant therapy. However, children with unresectable tumors often experience multiple progressions and require additional treatment.

Conventional chemotherapy

Radiotherapy results in long-term tumor control, but it is associated with significant toxicity, making chemotherapy the preferred therapeutic option. Several chemotherapy combinations have been found to be successful in PLGG, but 5-year EFS has been below 60 % with most of them.

Molecular-based treatment

Recent molecular advances have led to a better understanding of the molecular pathways involved in the biology of LGG, allowing the development of promising tumor-specific, molecularly targeted therapies.

Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J, Wolinsky Y, Krucho C, Barnholtz-Sloan J (2014) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro Oncol 16(Suppl 4):iv1-63

Garzón M, García-Fructuoso G, Suñol M, Mora J, Cruz O (2013) Low-grade gliomas in children: single institutional experience. Childs Nerv Syst 31:1321–1331CrossRef

Bandopadhayay P, Bergthold G, London WB, Goumnerova LC, Morales La Madrid A, Marcus KJ, Guo D, Ullrich NJ, Robison NJ, Chi SN, Beroukhim R, Kieram MW, Manley PE (2014) Long-term outcome of 4040 children diagnosed with pediatric low-grade gliomas: an analysis of the Surveillance Epidemiology and End Results (SEER) database. Pediatr Blood Cancer 61:1173–1179CrossRefPubMedPubMedCentral

Stokland T, Liu JF, Ironside JW, Ellison DW, Taylor R, Robinson KJ, Picton SV, Walker DA (2010) A multivariate analysis of factors determining tumor progression in childhood low-grade glioma: a population based cohort study (CCLG CNS9702). Neuro Oncol 12:1257–1268PubMedPubMedCentral

Youland RS, Khwaja SS, Schomas DA, Keating GS, Wetjen M, Laack NN (2013) Prognostic factors and survival patterns in pediatric low-grade gliomas over 4 decades. J Pediatr Hematol Oncol 35:197–205CrossRefPubMed

Chalil A, Ramaswamy V (2016) Low grade gliomas in children. J Child Neurol 31:517–522CrossRefPubMed

Chamdine O, Broniscer A, Wu S, Gajjar A, Qaddoumi I (2016) Metastatic low-grade gliomas in children: 20-years’ experience at St. Jude Children’s Research Hospital. Pediatr Blood Cancer 63:62–70CrossRefPubMed

Wisoff JH, Sanford RA, Heier LA, Sposto R, Burger PC, Yates AJ, Holmes EJ, Kun LE (2011) Primary neurosurgery for pediatric low-grade gliomas: a prospective multi-institutional study from the Children’s Oncology Group. Neurosurgery 68:1548–1555CrossRefPubMed

Müller K, Gnekow A, Falkstein F, Scheiderbauer J, Zwiener I, Pietsch T, Warmuth-metz M, Voges J, Nikkhah G, Flentje M, Combs SE, Vordemark D, Kocher M, Kortmann RD (2013) Radiotherapy in pediatric pilocytic astrocytomas. A subgroup analysis within the prospective multicenter study HIT-LGG 1996 by the German Society of Pediatric Oncology and Hematology (GPOH). Strahlenther Onkol 189:647–655CrossRefPubMed

10.

Raikar SS, Halloran DR, Elliot M, McHugh M, Patel S, Gauvain KM (2014) Outcomes of pediatric low-grade gliomas treated with radiation therapy: a single institution study. J Pediatr Hematol Oncol 36:e366–e370CrossRefPubMedPubMedCentral

11.

Williams NL, Rotondo RL, Bradley JA, Pincus DW, Fort JA, Wynn T, Morris CG, Mendenhall NP, Indelicato DJ (2016) Late effects after radiotherapy for childhood low-grade glioma. Am J Clin Oncol. doi:10.1097/COC.0000000000000267

12.

Nwachukwu CR, Youland RS, Chioreso C, Wetjen N, NageswaraRao A, Keating G, Laack NN (2015) Health related quality of life (HRQOL) in long term survivors of pediatric low grade gliomas (LGGs). J Neurooncol 121:599–607CrossRefPubMed

13.

Nageswara Rao AA, Packer RJ (2014) Advances in the management of low-grade gliomas. Curr Oncol Rep 16:398CrossRefPubMed

14.

Guerreiro Stucklin AS, Tabori U, Grotzer MA (2016) The changing landscape of pediatric low-grade gliomas: clinical challenges and emerging therapies. Neuropediatrics 47:70–83CrossRefPubMed

15.

Khatua S, Wang J, Rajaram V (2015) Review of low-grade gliomas in children—evolving molecular era and therapeutics insights. Childs Nerv Systm 31-643-652

16.

Raabe E, Kieran MW, Cohen KJ (2013) New strategies in pediatric gliomas: molecular advances in pediatric low-grade gliomas as a model. Clin Cancer Res 19:4553–4558CrossRefPubMedPubMedCentral

17.

Packer RJ, Lange B, Ater J, Nicholson HS, Allen J, Walker R, Prados M, Jakacki R, Reaman G, Needles MN (1993) Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood. J Clin Oncol 11:850–856PubMed

18.

Packer RJ, Ater J, Allen J, Phillips P, Geyer R, Nicholson HS, Jakacki R, Kurczynski E, Needle M, Finlay J, Reaman G, Boyett JM (1997) Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg 86:747–754CrossRefPubMed

19.

Gnekow AK, Falkenstein F, von Hornstein S, Zwiener I, Berkefeld S, Bison B, Warmuth-Metz M, Hernáiz driever P, Sorensen N, Kortmann RD, Pietsch T, Faldum A (2012) Long-term follow-up of the multicenter, multidisciplinary treatment study HIT-LGG-1996 for low grade glioma in children and adolescents of the German Speaking Society of Pediatric Oncology and Hematology. Neuro Oncol 14:1265–1284CrossRefPubMedPubMedCentral

20.

Gnekow AK, Kandels D, Walker DA, Perilongo G, Grill J, Stokland T, Sehested AM, van Schouten AYN, de Paoli A, de Salvo GL (2014) Abstracts from the sixteenth international symposium on pediatric neuro-oncology: a randomized trial of intensification of induction chemotherapy within an 18 months treatment-strategy on tumor response at 24 weeks and progression-free-survival in pediatric low grade glioma (LGG). Preliminary results of the SIOP-LGG-2004-Working Group. Neuro Oncol 16:i60–i70CrossRef

21.

Genc DB, Canpolat C, Berrak SG (2012) Clinical features and management of carboplatin-related hypersensitivity reactions in pediatric low-grade glioma. Support Care Cancer 20:385–393CrossRefPubMed

22.

Massimino M, Spreafico F, Cefalo G, Riccardi R, Tesoro-Tess JD, Gandola L, Riva D, Ruggiero A, Valentini L, Mazza E, Genitori L, di Rocco C, Navarria P, Casanova M, Ferrari A, Luksch R, Terenziani M, Balestrini MR, Colosimo C, Fossati-Bellani F (2002) High response rate to cisplatin/etoposide regimen in children with low-grade glioma. J Clin Oncol 20:4209–4216CrossRefPubMed

23.

Massimino M, Spreafico F, Riva D, Biassoni V, Poggi G, Solero C, Gandola L, Genitori L, Modena P, Simonetti F, Potepan P, Casanova M, Meazza C, Clerici CA, Catania S, Sardi I, Giangaspero F (2010) A lower dose, lower toxicity regimen for childhood progressive low-grade glioma. J Neurooncol 100:65–71CrossRefPubMed

24.

Prados ME, Edwards MSB, Rabbitt J, Lamborn K, Davies RL, Levin VA (1997) Treatment of pediatric low-grade gliomas with a nistrosurea-based multiagent chemotherapy regimen. J Neurooncol 32:235–241CrossRefPubMed

25.

Mishra KK, Squire S, Lamborn K, Banerjee A, Gupta N, Wara WM, Prados MD, Berger MS, Haas-Kogan DA (2010) Phase II TPDCV protocol for pediatric low-grade hypothalamic/chiasmatic gliomas: 15 year update. J Neurooncol 100:121–127CrossRefPubMedPubMedCentral

26.

Ater JL, Zhou T, Holmes E, Mazewski CM, Booth TN, Freyer DR, Lazarus KH, Packer RJ, Prados M, Sposto R, Vezina G, Wisoff JH, Pollack IF (2012) Randomized study of two chemotherapy regimens for treatment of low grade glioma in young children: a report from the Children’s Oncology Group. J Clin Oncol 30:2641–2647CrossRefPubMedPubMedCentral

27.

Singh G, Wei XC, Hader W, Chan JA, Bouffet E, Lafay-Cousin L (2013) Sustained response of weekly vinblastine in 2 children with pilomyxoid astrocytoma associated with diencephalic syndrome. J Pediatr Hematol Oncol 35:e53–e56CrossRefPubMed

28.

Bouffet E, Jakacki R, Goldman S, Hargrave D, Hawkins C, Shroff M, Hukim J, Bartels U, Foreman N, Kellie S, Hilden J, Etzl M, Wilson B, Stephens D, Tabori U, Baruchel S (2012) Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma. J Clin Oncol 30:1358–1363CrossRefPubMed

29.

National Cancer Institute: weekly vinblastine for chemotherapy naive children with progressive low grade glioma (PLGGs). http://clinicAltrials.gov/ct2/show/NCT00575796

30.

Cappellano AM, Petrilli AS, da Silva NS, Silva FA, Paiva PM, Cavalheiro S, Bouffet E (2015) Single agent vinorelbine in pediatric patients with progressive optic pathway glioma. J Neurooncol 121:405–412CrossRefPubMed

31.

Lashkari HP, Saso S, Moreno L, Athanasiou T, Zacharoulis S (2011) Using different schedules of temozolomide to treat low grade gliomas: systematic review of their efficacy and toxicity. J Neurooncol 1055:135–147CrossRef

32.

Gururangan S, Fisher MJ, Allen JC, Herndon JE, Quinn JA, Reardon DA, Vredenburgh JJ, Desjardins A, Phillips PC, Watral MA, Krauser JM, Friedman AH, Friedman HS (2007) Temozolomide in children with progressive low-grade glioma. Neuro Oncol 9:161–168CrossRefPubMedPubMedCentral

33.

Khaw SL, Coleman LT, Downie PA, Heath JA, Ashley DM (2007) Temozolomide in pediatric low grade glioma. Pediatr Blood Cancer 49:808–811CrossRefPubMed

34.

Nicholson HS, Kretschmar CS, Krailo M, Berstein M, Kadota R, Fort D, Friedman H, Harris MB, Tedeschi-Blok N, Mazewski C, Sato J, Reaman GH (2007) Phase II study of temozolomide in children and adolescents with recurrent central nervous system tumors. A report from the Children Oncology Group. Cancer 110:1542–1550CrossRefPubMed

35.

Kuo DJ, Weiner HL, Wissoff J, Miller DC, Knopp EA, Finlay JL (2003) Temozolomide is active in childhood, progressive, unresectable, low grade gliomas. J Pediatr Hematol Oncol 25:372–378CrossRefPubMed

36.

Packer RJ, Jakacki RI, Horn M, Rood B, Vezina G, MacDonald T, Fisher MJ, Cohen B (2009) Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan. Pediatr Blood Cancer 52:791–795CrossRefPubMed

37.

Hwang EI, Jakacki RI, Fisher MJ, Kilburn LB, Horn M, Vezina G, Rood BR, Packer RJ (2013) Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas. Pediatr Blood Cancer 60:776–782CrossRefPubMed

38.

Gururangan S, Fangusaro J, Young Poussaint T, McLendon RE, Onar-Thomas A, Wu S, Packer RJ, Banerjee A, Gilbertson RJ, Fahey F, Vajapeyam S, Jakacki R, Gajjar A, Goldman S, Pollack IF, Friedman HS, Boyett JM, Fouladi M, Kun LE (2014) Efficacy of bevacizumab plus irinotecan in children with recurrent low grade gliomas—a Pediatric Brain Tumor Consortium study. Neuro Oncol 16:310–317CrossRefPubMed

39.

Mirow C, Pietsch T, Berkefeld S, Kwiecien R, Warmuth-Metz M, Falkenstein F, Diehl B, von Hornstein S, Gnekow AK (2014) Children < 1 year show an inferior outcome when treated according to the traditional LGG treatment strategy: a report from the German multicenter trial HIT-LGG 1996 for children with low grade glioma (LGG). Pediatr Blood Cancer 61:457–463CrossRefPubMed

40.

von Hornstein S, Kortmann RD, Pietsch T, Emser A, Warmuth-Metz M, Soerensen N, Straeter R, Graf N, Thieme B, Gnekow AK (2011) Impact of chemotherapy on disseminated low-grade glioma in children and adolescents: report from the HIT-LGG 1996 trial. Pediatr Blood Cancer 56:1046–1054CrossRef

41.

Louis DN, Perry A, Burger P, Ellison DW, Reifenberger G, von Deimling A, Aldape K, Brat D, Collins VP, Eberhart C, Figarella-Branger D, Fuller GN, Giangaspero F, Giannini C, Hawkins C, Kleihues P, Korsunov A, Kros JM, Beatriz Lopes M, Ng HK, Ohgaki H, Paulus W, Pietsch T, Rosemblum M, Rushing E, Soylemezoglu F, Wiestler O, Wesseling P (2014) International Society of Neuropathology-Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol 24(5):429–435CrossRefPubMed

42.

Hernáiz Driever P, von Hornstein S, Pietsch T, Kortmann R, Warmuth-Metz M, Emser A, Gnekow AK (2010) Natural history and management of low-grade glioma in NF-1 children. J Neurooncol 100(2):199–207CrossRefPubMed

43.

Penman CL, Faulkner C, Lowis SP, Murian KM (2015) Current understanding of BRAF alterations in diagnosis, prognosis, and therapeutic targeting in pediatric low-grade gliomas. Front Oncol 5:Art 54. doi:10.3389/fonc.2015.00054

44.

Bar EE, Lin A, Tihan T, Burger PC, Eberhart CG (2008) Frequent gains al chromosome 7q34 involving BRAF in pilocytic astrocytoma. J Neuropathol Exp Neurol 67:878–887CrossRefPubMed

45.

Lin A, Rodriguez FJ, Karajjanis MA, Williams SC, Legault G, Zaqzaq D, Burger PC, Allen JC, Eberhart CG, Bar EE (2012) BRAF alterations in primary glial and glioneuronal neoplasms of the central nervous system with identification of two novel KIAA1549-BRAF fusion variants. J Neuropathol Exp Neurol 71:66–72CrossRefPubMedPubMedCentral

46.

Hawkins C, Walker E, Mohamed N, Zhang C, Jacob K, Shirinian M, Alon N, Khan D, Fried I, Scheinemann K, Tsangaris E, Dirks P, Tressler R, Bouffet E, Jabado N, Tabori U (2011) BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma. Clin Can Res 17:4790–4798CrossRef

47.

Jacob K, Albrecht S, Sollier C, Faury D, Sader E, Montpetit A, Serre D, Hauser P, Garami M, Bognar L, Hanzely Z, Montes JL, Atkinson J, Farmer JP, Bouffet E, Hawkins C, Tabori U, Jabado N (2009) Duplication of 7q34 is specific to juvenile pilocytic astrocytomas and a hallmark of cerebellar and optic pathway tumors. Br J Can 101:722–733CrossRef

48.

Cin H, Meyer C, Janzarik WG, Lambert S, Jones DT, Jacob K, Benner A, Witt H, Remke M, Bender S, Falkenstein F, Van Anh TN, Olbrich H, von Deimling A, Pekrun A, Kulozik AE, Gnekow A, Scheurlen W, Witt O, Omran H, Jabado N, Collins VP, Brummer T, Marschalek R, Lichter P, Korshunov A, Pfister (2011) Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. Acta Neuropathol 121:763–774CrossRefPubMed

49.

Zhang J, Wu G, Miller CP, Tatevossian RG, Dalton JD, Tang B, Orisme W, Punchihewa C, Parker M, Qaddaoumi I, Boop FA, Lu C, Kandoth C, Ding L, Lee R, Huether R, Chen X, Hedlund E, Nagahawatte P, Rusch M, Boggs K, Cheng J, Becksfort J, Ma J, Song G, Li Y, Wei L, Wang J, Shurtleff S, Easton J, Zhao D, Fulton RS, Fulton LL, Dooling D, Vadodaria B, Mulder HL, Tang C, Ochoa K, Mullighan CG, Gajjar A, Kriwacki R, Sheer D, Gilbertson RJ, Mardis ER, Wilson RK, Downing JR, Ellison DW (2013) Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet 45(6):602–612CrossRefPubMedPubMedCentral

50.

Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C, Schmieder K, Wesseling P, Mawrin C, Hasselblatt M, Louis DN, Korshunov A, Pfister S, Hartmann C, Paulus W, Reifenberger G, von Deimling A (2011) Analysis of BRAF^V600E mutation in 1320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, gsnglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 121:397–405CrossRefPubMed

51.

Dahiya S, Haydon DH, Alvarado D, Gurnett CA, Gutmann DH, Leonard JR (2013) BRAF(V600E) mutation is a negative prognosticator in pediatric ganglioglioma. Acta Neuropathol 125(6):901–910CrossRefPubMed

52.

Hassan B, Akcakanat A, Holder AM, Meric-Bernstam F (2013) Targeting the PI3 kinase (Akt/m-TOR signaling pathway. Surg Oncol Clin N Am 22(4):641–664CrossRefPubMed

53.

Rush S, Foreman N, Liu A (2013) Brainstem ganglioglioma successfully treated with vemurafenib. J Clin Oncol 31(e1):59–60

54.

Nicolaides TP, Solomon DA, Hariono S, Hashizume R (2011) Targeted therapy for BRAFV600E malignant astrocytoma. Clin Cancer Res 17:7595–7604CrossRefPubMedPubMedCentral

55.

del Bufalo F, Carai A, Figà-Talamanca L, Pettorini B, Mallucci C, Giangaspero F, Antonelli M, Badiali M, Moi L, Bianco G, Cacchione A, Locatelli F, Ferretti E, Mastronuzzi A (2014) Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent. J Transl Med 12:356CrossRefPubMedPubMedCentral

56.

Skrypek M, Foreman N, Guillaume D, Moertel C (2014) Pylomixoid astrocytoma treated successfully with vemurafenib. Ped Blood Can 61(11):2099CrossRef

57.

García MA, Solomon DA, Haas-Kogan DA (2016) Exploiting molecular biology for diagnosis and targeted management of pediatric low grade gliomas. Future Oncol 12(12):1493–1506

58.

Karajannis MA, Fisher MJ, Milla SS, Cohen KJ, Wissoff JH, Harter DH, Goldberg JD, Hochman T, Merkelson A, Bloom MC, Sievert AJ, Resnick AC, Dhall G, Jones DT, Korshunov A, Pfister SM, Eberhart CG, Zagzag D, Allen JC (2014) Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas. Neuro Oncol 16(10):1408–1416CrossRefPubMedPubMedCentral

59.

Franz DN, Leonard J, Tudor C, Chuck G, Care M, Sethuraman G, Dinopoulos A, Thomas G, Crone KR (2006) Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 59:490–498CrossRefPubMed

60.

Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, Wilson KA, Byars A, Sahmoud T, Franz DN (2010) Everolimus for subependymal giant cell astrocytomas in tuberous sclerosis. N Engl J Med 363:1801–1811CrossRefPubMed

61.

Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, Witt O, Khhrman MH, Flamini JR, Wu JY, Curatolo P, de Vries PJ, Whittemore VH, Thiele EA, Ford JP, Shah G, Cauwel H, Lebwohl D, Sahmoud T, Jozwiak S (2013) Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 381:125–132CrossRefPubMed

62.

Yalon M, Rood B, MacDonald TJ, McCowage G, Kane R, Constantini S, Packer RJ (2013) A feasibility and efficacy study of rapamycin and erlotinib for recurrent pediatric low-grade glioma (LGG). Ped Blood Can 60:71–76CrossRef

63.

Dubois SG, Shusterman S, Ingle AM, Ahern CH, Reid JM, Wu B, Baruchel S, Glade-Bender J, Ivy P, Grier HE, Adamson PC, Blaney SM (2011) Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors; a Children’s Oncology Group Study. Clin Cancer Res 17:5113–5122CrossRefPubMedPubMedCentral

Titel: Conventional chemotherapy and perspectives for molecular-based oncological treatment in pediatric hemispheric low-grade gliomas
verfasst von: María Baro Fernández
Vanesa Pérez Alonso
Publikationsdatum: 01.10.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: Child's Nervous System / Ausgabe 10/2016
Print ISSN: 0256-7040
Elektronische ISSN: 1433-0350
DOI: https://doi.org/10.1007/s00381-016-3132-0

Neu im Fachgebiet Chirurgie

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Wie sieht der OP der Zukunft aus?

04.05.2024 DCK 2024 Kongressbericht

Der OP in der Zukunft wird mit weniger Personal auskommen – nicht, weil die Technik das medizinische Fachpersonal verdrängt, sondern weil der Personalmangel es nötig macht.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Recycling im OP – möglich, aber teuer

02.05.2024 DCK 2024 Kongressbericht

Auch wenn sich Krankenhäuser nachhaltig und grün geben – sie tragen aktuell erheblich zu den CO₂-Emissionen bei und produzieren jede Menge Müll. Ein Pilotprojekt aus Bonn zeigt, dass viele Op.-Abfälle wiederverwertet werden können.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare

CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare

CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare

CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Springer Medizin

Abstract

Introduction

Conventional chemotherapy

Molecular-based treatment

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2016

Cerebral hemispheric low-grade glial tumors in children: preoperative anatomic assessment with MRI and DTI

The relationship between transorbital ultrasound measurement of the optic nerve sheath diameter (ONSD) and invasively measured ICP in children.

Awake surgery for hemispheric low-grade gliomas: oncological, functional and methodological differences between pediatric and adult populations

An integrative molecular and genomic analysis of pediatric hemispheric low-grade gliomas: an update

Supratentorial tumors typical of the infantile age: desmoplastic infantile ganglioglioma (DIG) and astrocytoma (DIA). A review

PET and SPECT studies in children with hemispheric low-grade gliomas

Update Chirurgie